Recent discussions on X about Skye Bioscience (SKYE) have centered around the company’s Q2 2025 earnings report, which highlighted a significant surge in research and development spending. Many users expressed concern over the financial impact of these investments, noting a subsequent dip in the stock price as reported by Investing.com. The tone reflects a cautious outlook, with some questioning whether upcoming trial results will justify the costs.
Despite the financial concerns, there is a flicker of optimism among certain X users who see potential in Skye Bioscience’s strategic focus on R&D as a long-term growth driver. Posts on the platform suggest that key upcoming events could serve as catalysts for a rebound if results are favorable. The conversation remains dynamic, with investors keenly watching for further developments.
Note: This discussion summary was generated from an AI condensation of post data.
Skye Bioscience Insider Trading Activity
Skye Bioscience insiders have traded $SKYE stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $SKYE stock by insiders over the last 6 months:
- ANDREW J. SCHWAB has made 0 purchases and 4 sales selling 231,405 shares for an estimated $800,548.
- PARTNERS VII, LLC 5AM has made 0 purchases and 4 sales selling 231,405 shares for an estimated $800,548.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Skye Bioscience Hedge Fund Activity
We have seen 25 institutional investors add shares of Skye Bioscience stock to their portfolio, and 54 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SPHERA FUNDS MANAGEMENT LTD. removed 937,919 shares (-63.5%) from their portfolio in Q2 2025, for an estimated $3,920,501
- BRAIDWELL LP removed 825,732 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,451,559
- BLACKROCK, INC. removed 789,075 shares (-65.7%) from their portfolio in Q2 2025, for an estimated $3,298,333
- SCHONFELD STRATEGIC ADVISORS LLC removed 519,260 shares (-32.1%) from their portfolio in Q2 2025, for an estimated $2,170,506
- MILLENNIUM MANAGEMENT LLC added 470,729 shares (+inf%) to their portfolio in Q2 2025, for an estimated $1,967,647
- STATE STREET CORP removed 303,214 shares (-82.0%) from their portfolio in Q2 2025, for an estimated $1,267,434
- CITADEL ADVISORS LLC removed 250,014 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $397,522
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Skye Bioscience Analyst Ratings
Wall Street analysts have issued reports on $SKYE in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JMP Securities issued a "Market Outperform" rating on 06/24/2025
- Craig-Hallum issued a "Buy" rating on 03/21/2025
- Citizens Capital Markets issued a "Market Outperform" rating on 03/21/2025
- William Blair issued a "Outperform" rating on 02/28/2025
To track analyst ratings and price targets for Skye Bioscience, check out Quiver Quantitative's $SKYE forecast page.
Skye Bioscience Price Targets
Multiple analysts have issued price targets for $SKYE recently. We have seen 4 analysts offer price targets for $SKYE in the last 6 months, with a median target of $14.5.
Here are some recent targets:
- Michael DiFiore from Evercore ISI Group set a target price of $10.0 on 08/15/2025
- Jonathan Wolleben from JMP Securities set a target price of $15.0 on 06/24/2025
- Albert Lowe from Craig-Hallum set a target price of $14.0 on 03/21/2025
- Jonathan Wolleben from Citizens Capital Markets set a target price of $15.0 on 03/21/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
